阿帕替尼联合放疗对非小细胞肺癌患者血清肿瘤标志物及生存质量的影响  

Effect of Apatinib Combined with Radiotherapy on Serum Tumor Markers and Quality of Life in Patients with Non-Small Cell Lung Cancer

作　　者：刘楚基 颜劲[1] 陈敏[1] Liu Chuji(Zhanjiang Central People's Hospital,Zhanjiang,Guangdong 524000)

机构地区：[1]湛江中心人民医院,广东湛江524000

出　　处：《黑龙江医药》2021年第3期503-506,共4页Heilongjiang Medicine journal

基　　金：湛江市科技计划项目(编号:2019B01180)。

摘　　要：目的:探讨非小细胞肺癌(NSCLC)患者应用阿帕替尼联合放疗治疗的效果。方法:选取我院2017年12月至2019年12月收治的NSCLC患者82例,采用随机数字表法分为两组。对照组41例患者采用常规放疗,观察组41例患者采用阿帕替尼联合放疗。治疗1个月后,比较两组肿瘤标志物[细胞角蛋白19片段抗原21-1(CYFRA21-1)和癌胚抗原(CEA)]、生活质量以及不良反应。结果:观察组生存质量改善率(87.80%)高于对照组(68.29%),观察组治疗后CYFRA211水平、CEA水平低于对照组,差异有统计学意义(P<0.05);观察组与对照组不良反应发生率相比,差异无统计学意义(P>0.05)。结论:非小细胞癌患者采用常规放疗治疗基础上,配合阿帕替尼治疗能降低肿瘤标志物水平,提高患者生活质量,且安全可靠。Objective:To investigate the effect of apatinib combined with radiotherapy on serum tumor markers and quality of life in patients with non-small cell lung cancer.Methods:A total of 82 patients with non-small cell lung cancer admitted to our hospital from December 2017 to December 2019 were selected and divided into two groups by random number table.41 patients in the control group received conventional radiotherapy,and 41 patients in the observation group received apatinib combined with radiotherapy.After 1 month of treatment,the two groups of tumor markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and carcinoembryonic antigen(CEA)],the quality of life and the occurrence of adverse reactions were compared between the two groups.Results:The improvement rate of quality of life of the observation group(87.80%)was higher than that of the control group(68.29%).After treatment,the CYFRA211 level and CEA level of the observation group were lower than the control The difference of and in the group was statistically significant(P<0.05);the difference in the incidence of adverse reactions between the observation group and the control group was not statistically significant(P>0.05).Conclusion:On the basis of conventional radiotherapy for patients with non-small cell carcinoma,treatment with apatinib can reduce the level of tumor markers and improve the quality of life of patients without increasing adverse reactions.It is safe and feasible.

关 键 词：非小细胞肺癌 放疗 阿帕替尼 肿瘤标志物 生存质量 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]